
Eloxx Pharmaceuticals ELOX
Quartalsbericht 2023-Q3
hinzugefügt 13.11.2023
Eloxx Pharmaceuticals EV 2011-2025 | ELOX
EV Jährlich Eloxx Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 18.7 M | -18.3 M | 130 M | 149 M | 333 M | -12.6 M | 6.11 M | 14.7 M | 11.1 M | 5.81 M | 23.8 M | 18.5 M |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 333 M | -18.3 M | 56.6 M |
EV anderer Aktien in der Pharmaeinzelhändler
| Name | EV | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
ARCA biopharma
ABIO
|
436 M | - | 1052.0 % | $ 415 M | ||
|
AbbVie
ABBV
|
337 B | $ 223.98 | -0.53 % | $ 396 B | ||
|
Alpine Immune Sciences
ALPN
|
363 M | - | - | $ 2.17 B | ||
|
Arbutus Biopharma Corporation
ABUS
|
457 M | $ 4.67 | 1.74 % | $ 775 M | ||
|
Aclaris Therapeutics
ACRS
|
192 M | $ 3.36 | 2.75 % | $ 260 M | ||
|
AlloVir
ALVR
|
-64.1 M | - | 4.14 % | $ 49.1 M | ||
|
Acasti Pharma
ACST
|
24 M | - | 4.01 % | $ 150 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
2.15 B | - | -15.15 % | $ 60.3 M | ||
|
Ampio Pharmaceuticals
AMPE
|
-1.05 M | - | -11.43 % | $ 502 K | ||
|
Aeglea BioTherapeutics
AGLE
|
725 M | - | - | $ 1.01 B | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
1.95 B | - | - | $ 40.3 B | ||
|
Albireo Pharma
ALBO
|
417 M | - | -0.23 % | $ 916 M | ||
|
Ascendis Pharma A/S
ASND
|
726 M | $ 210.16 | 4.43 % | $ 5 B | ||
|
Ayala Pharmaceuticals
AYLA
|
5.32 M | - | - | $ 7.46 M | ||
|
Aptorum Group Limited
APM
|
9.45 M | $ 1.33 | -1.48 % | $ 7.25 M | ||
|
Alterity Therapeutics Limited
ATHE
|
-28.9 M | $ 3.42 | 2.09 % | $ 8.23 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
3.41 B | - | -1.52 % | $ 24.7 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
2 B | $ 25.9 | 0.74 % | $ 1.25 B | ||
|
AstraZeneca PLC
AZN
|
57.7 B | $ 90.29 | - | $ 96.9 B | ||
|
Anika Therapeutics
ANIK
|
300 M | $ 9.49 | - | $ 139 M | ||
|
Brickell Biotech
BBI
|
515 K | - | -5.38 % | $ 6.06 M | ||
|
BeiGene, Ltd.
BGNE
|
253 B | - | 0.49 % | $ 251 B | ||
|
Bellicum Pharmaceuticals
BLCM
|
-9.74 M | - | -9.72 % | $ 5.89 M | ||
|
Berkeley Lights
BLI
|
115 M | - | -7.31 % | $ 87 M | ||
|
Aytu BioScience
AYTU
|
-15.2 M | $ 2.28 | - | $ 14.3 M | ||
|
Arena Pharmaceuticals
ARNA
|
5.65 B | - | -6.81 % | $ 3.04 B | ||
|
Biogen
BIIB
|
28.3 B | $ 172.5 | - | $ 25.1 B | ||
|
Baudax Bio
BXRX
|
29.8 M | - | 0.59 % | $ 63 K | ||
|
Avenue Therapeutics
ATXI
|
-1.23 M | - | -52.27 % | $ 4.45 M | ||
|
Benitec Biopharma
BNTC
|
461 M | $ 12.96 | 1.17 % | $ 533 M | ||
|
Институт стволовых клеток человека
ISKJ
|
14.1 M | - | - | - | ||
|
ChromaDex Corporation
CDXC
|
408 M | - | -0.88 % | $ 598 M | ||
|
Axon Enterprise
AXON
|
41.5 B | $ 581.03 | 2.22 % | $ 44 B | ||
|
Can-Fite BioPharma Ltd.
CANF
|
647 M | $ 0.29 | -0.31 % | $ 631 M | ||
|
Checkpoint Therapeutics
CKPT
|
174 M | - | - | $ 169 M | ||
|
Caladrius Biosciences
CLBS
|
-6.94 M | - | -16.75 % | $ 25.8 M | ||
|
Catalyst Biosciences
CBIO
|
38.1 M | $ 15.31 | - | $ 1.01 B | ||
|
Clovis Oncology
CLVS
|
839 M | - | -7.23 % | $ 13 M | ||
|
Cerus Corporation
CERS
|
425 M | $ 2.15 | 13.76 % | $ 397 M | ||
|
BioVie
BIVI
|
-12.6 M | $ 1.51 | -4.43 % | $ 2.23 M | ||
|
Cortexyme
CRTX
|
132 M | - | -1.05 % | $ 67.1 M | ||
|
Celldex Therapeutics
CLDX
|
18.3 M | $ 27.94 | - | $ 1.8 M | ||
|
Cellectar Biosciences
CLRB
|
60.8 M | $ 3.78 | -5.97 % | $ 46.2 M | ||
|
Deciphera Pharmaceuticals
DCPH
|
1.24 B | - | - | $ 2.18 B | ||
|
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
10.2 B | $ 11.44 | 7.92 % | $ 740 M | ||
|
BioNTech SE
BNTX
|
-6.64 B | $ 96.0 | - | $ 27.2 B | ||
|
Acer Therapeutics
ACER
|
38.2 M | - | 2.71 % | $ 14 M | ||
|
Enochian Biosciences
ENOB
|
145 M | - | - | $ 40.5 M | ||
|
Epizyme
EPZM
|
4.31 M | - | - | $ 249 M |